Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31042133 | 0.80 | CYP11B1 (0.36) | MAOBMAOAPTPN1 | |
| SCHEMBL3928046 | 0.79 | KCNA3 (0.46) | MAOBMAOAFTODRD2DRD1 | |
| SCHEMBL32691417 | 0.79 | KMT2A (0.44) | MAOBMAOACA12FTO | |
| SCHEMBL32691372 | 0.79 | DAO (0.33) | MAOBMAOAPTPN1DRD2DRD4 | |
| SCHEMBL15447339 | 0.79 | MAPT (0.43) | CA2CA1CA9 | |
| SCHEMBL4504937 | 0.79 | PTGS1 (0.36) | CA2CA12CA9 | |
| SCHEMBL3771766 | 0.79 | PTPN1 (0.41) | MAOBMAOAPTPN1 | |
| SCHEMBL12986005 | 0.77 | KCNA3 (0.51) | MAOBCA12CA1CA9 | |
| SCHEMBL6851155 | 0.77 | MEN1 (0.38) | CA2CA1CA9DRD2DRD1 | |
| SCHEMBL2083806 | 0.77 | PIN1 (0.48) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116239562-A | Method for synthesizing doxepin hydrochloride by taking benzofuranone as raw material | 江苏师范大学 | 2023-06-09 | — | — | CN | claimed |
| CN-116239562-A | Method for synthesizing doxepin hydrochloride by taking benzofuranone as raw material | 江苏师范大学 | 2023-06-09 | — | — | CN | disclosed |
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-5665722-A | Benzofuran derivatives as D4 receptor antagonists | MERCK, SHARP & DOHME, LTD. (GB) | 1997-09-09 | — | — | US | disclosed |
| EP-0757686-A1 | BENZOFURAN DERIVATIVES AS D 4? RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029911-A1 | BENZOFURAN DERIVATIVES AS D4 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | MAOB 2184/4885CA2 1554/4885MAOA 776/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | MAOB 2935/4885CA2 1725/4885MAOA 1018/4885 |
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | MAOB 1270/4885CA2 1736/4885MAOA 2048/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | MAOB 3331/4885CA2 1009/4885MAOA 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.